secwatch.observer — SEC 8-K summary
======================================

Issuer:     DAXOR CORP (DXR)
CIK:        0000027367
Form:       8-K
Filed at:   2022-01-24T23:59:59+00:00
Accession:  0001493152-22-002107
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Daxor appoints Caleb DesRosiers to Board of Directors
-----------------------------------------------------

- Caleb DesRosiers, JD, MPA, appointed to Board effective January 18, 2022, until next annual meeting.
- Currently senior principal at Valuate Healthcare (part of Omnicom); previously Chief Strategy Officer at PrescribeWellness.
- Board determined Mr. DesRosiers meets NYSE independence standards and qualifies under Regulation S-K Item 407(a).
- He has no beneficial ownership of Daxor stock or rights to acquire stock as of appointment date.
- Will receive standard non-employee director compensation as described in the company's proxy statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/27367/000149315222002107/0001493152-22-002107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/27367/000149315222002107/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-002107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer